After finding a violation, the Food and Drugs Administration (FDA) has ordered a halt to the airing of the dengue vaccine advertisements of Sanofi Philippines.
Sanofi for its part said their ads were in compliance with FDA standards.
The Philippines is among the first markets for Dengvaxia. The pharmaceutical breakthrough was first made available in Mexico in December 2015 and was shortly also distributed in Asia.
However, the Department of Health’s (DOH) distribution of the first ever dengue vaccine was stained with controversy last year for alleged kickbacks in the procurement worth P3.5 billion.
Former health secretary Janette Garin has since denied the allegations, stating that amount was part of the DOH’s 2015 budget that benefited 280,000 grade 4 public school students.
Dengvaxia was developed after 20 years of regulated clinical and laboratory tests conducted on children in countries like the Philippines where dengue is still prevalent and causes serious health cases with some leading to death.